Skip to main content
OpenTrials
Completed

NCT Number: NCT01625871

Artemether/Lumefantrine and Vivax Malaria

The cure rate of artemether/lumefantrine in the treatment of vivax malaria.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Vivax Malaria Infections Malaria Malaria, Vivax Mosquito-Borne Diseases Parasitic Diseases Protozoan Infections Vector Borne Diseases

Age range

5 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Kassala

Kassala, 249, Sudan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with vivax malaria

Exclusion criteria

  • severe malaria
  • pregnancy

Treatment and study plan

tablets artemether/lumefantrine

Drug

six doses of oral tablets of artemether/lumefantrine

Other names: Quartem

Primary outcomes

  1. The cure rate

    Time frame: 28 days

    The proportion of the cure patients

Secondary outcomes

  1. Fever clearance time

    Time frame: 28 days

    The time for fever clearance

  2. Parasite clearance time

    Time frame: 28 days

    The time for the parasite to clear

Sponsors and collaborators

Lead sponsor

University of Khartoum

Other

Collaborators

  • University of Kassala, Sudan

Registry information

Official study title

Artemether/Lumefantrine in the Treatment of Plasmodium Vivax Malaria in Eastern Sudan

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Jun 22, 2012
Registry last updated
Jan 17, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.